Published TCIMAIL newest issue No.197 | New tool "TCI SpectraViewer" | [TCIPracticalExample] The Synthesis of Rubicene... | Product Document Searching Made Easy by 2D Code!
Maximum quantity allowed is 999
Please select the quantity
CAS RN: 31637-97-5 | Product Number: E1359
Etofibrate
×
![]()
×
Purity: >98.0%(GC)
Synonyms:
- 2-[2-(4-Chlorophenoxy)-2-methyl-1-oxopropoxy]ethyl 3-Pyridinecarboxylate
- 3-Pyridinecarboxylic Acid 2-[2-(4-Chlorophenoxy)-2-methyl-1-oxopropoxy]ethyl Ester
- 2-[[2-(4-Chlorophenoxy)-2-methylpropanoyl]oxy]ethyl Nicotinate
- Nicotinic Acid 2-[[2-(4-Chlorophenoxy)-2-methylpropanoyl]oxy]ethyl Ester
Product Documents:
| Size | Unit Price | Hyderabad | Japan* | Quantity |
|---|---|---|---|---|
| 50MG |
₹5,400.00
|
Contact Us | 7 |
|
| 250MG |
₹11,280.00
|
Contact Us | 14 |
|
*Upon orders receipt, Hyderabad stocks will be dispatched on the same day.
*Items available in Japan warehouse will be dispatched in 10-12 working days.
*INR price is exclusive of domestic taxes applicable.
*TCI frequently reviews storage conditions to optimize them. Please note that the latest information on the storage temperature for the products is described on our website.
| Product Number | E1359 |
| Purity / Analysis Method | >98.0%(GC) |
| Molecular Formula / Molecular Weight | C__1__8H__1__8ClNO__5 = 363.79 |
| Physical State (20 deg.C) | Solid |
| Storage Temperature | Refrigerated (0-10°C) |
| Condition to Avoid | Heat Sensitive |
| CAS RN | 31637-97-5 |
| Reaxys Registry Number | 497931 |
| PubChem Substance ID | 468591729 |
| Merck Index (14) | 3877 |
| MDL Number | MFCD00865727 |
Specifications
| Appearance | White to Almost white powder to crystal |
| Purity(GC) | min. 98.0 % |
| Melting point | 48.0 to 52.0 °C |
| NMR | confirm to structure |
Properties (reference)
| Melting Point | 50 °C |
| Boiling Point | 214 °C/0.3 mmHg |
GHS
Related Laws:
Transport Information:
Application
Etofibrate: A Hybrid Hypolipidemic Agent which Combines Nicotinic Acid (Niacin) with Clofibrate
Etofibrate is a hypolipidemic fibrate which combines nicotinic acid (niacin) [N0082] with clofibrate [C0941]. After contact with plasma hydrolases, both active constituents are gradually released in a controlled-release manner. The fibrates, including etofibrate, are lower elevated serum lipids by decreasing the low density lipoprotein (LDL) fraction rich in cholesterol and the very low density lipoprotein (VLDL) fraction rich in triglycerides. In addition, fibrates increase the high density lipoprotein (HDL) cholesterol fraction. (The product is for research purpose only.)
References
- Studies with etofibrate in the rat. Part I: Effects on glycerol, free fatty acid and triacylglycerol metabolism
- Studies with etofibrate in the rat. Part II: a comparison of the effects of prolonged and acute administration on plasma lipids, liver enzymes and adipose tissue lipolysis
- Comparative study on the in vivo and in vitro antilipolytic effects of etofibrate, nicotinic acid and clofibrate in the rat
- High performance liquid chromatographic determination of etofibrate and its hydrolysis products
Articles/Brochures
TCIMAIL
Product Documents (Note: Some products will not have analytical charts available.)
Safety Data Sheet (SDS)
Please select Language.
The requested SDS is not available.
Please Contact Us for more information.
Specifications
C of A & Other Certificates
Please enter Lot Number
Incorrect Lot Number. Please input only the 4-5 alphanumeric characters before the hyphen.
Sample C of A
This is a sample C of A and may not represent a recently manufactured lot of the product.
A sample C of A for this product is not available at this time.
Analytical Charts
Please enter Lot Number
Incorrect Lot Number. Please input only the 4-5 alphanumeric characters before the hyphen.
The requested analytical chart is not available. Sorry for the inconvenience.